The PKMYT1–ALDOA axis drives chemoresistance in cholangiocarcinoma by enhancing glycolysis and MRE11 lactylation
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2623500123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Wei Wu und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Drug Resistance, Neoplasm, Glycolysis, Bile Duct Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Oncode Institute, National natural science foundation of China, Shanghai Municipal Health Commission ().
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a highly aggressive biliary malignancy with limited responses to existing treatments. Gemcitabine plus cisplatin (GC) remains the standard first-line chemotherapy for advanced disease, but its clinical efficacy is suboptimal, and drug resistance frequently emerges in patients. Through high-throughput synergistic drug screening, we identified PKMYT1 as a key synthetic lethal target regulating the chemosensitivity of cholangiocarcinoma cells. Functional validation confirmed that the PKMYT1 small-molecule inhibitor RP6306 exerts robust synthetic lethal effects when used in combination with gemcitabine or cisplatin. Data from colony formation assays and a series of cellular functional experiments showed that genetic or pharmacological inhibition of PKMYT1 substantially compromises DNA damage repair (DDR) and induces massive DNA double-strand breaks. Further mechanistic investigations revealed that PKMYT1 binds to Aldolase A (encoded by the ALDOA gene) and enhances its enzymatic activity, thereby upregulating CCA glycolysis levels and inducing lactate accumulation, which ultimately elevates the lactylation level of MRE11, accelerates DDR and consequently drives chemoresistance in CCA. Both cell-derived and patient-derived xenograft models verified that combined treatment with RP6306 and GC markedly inhibits tumor growth in vivo. Taken together, this work reveals that the PKMYT1-ALDOA-mediated protein lactylation pathway acts as a critical regulator of chemoresistance in CCA. Targeting PKMYT1 could reverse chemotherapy resistance and enhance therapeutic outcomes for advanced CCA, offering a promising combination strategy for clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China.
- Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
- Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai 200438, China.
ORCID-Profile: René Bernards
Förderung
- Oncode Institute
- National natural science foundation of China
- Shanghai Municipal Health Commission ()
Zitieren
APA
Wu, W., Wang, J., Yang, W., Sun, Z., Sun, X., Wang, Y., Lian, S., Zheng, J., Zhou, Y., Shen, W., Hu, P., Guo, J., Wu, Q., Wang, S., Jia, Q., Yuan, S., Bernards, R., Qin, W., & Jin, H. (2026). The PKMYT1–ALDOA axis drives chemoresistance in cholangiocarcinoma by enhancing glycolysis and MRE11 lactylation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2623500123
Vancouver
Wu W, Wang J, Yang W, Sun Z, Sun X, Wang Y, et al. The PKMYT1–ALDOA axis drives chemoresistance in cholangiocarcinoma by enhancing glycolysis and MRE11 lactylation. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2623500123
BibTeX
@article{Wu2026,
author = {Wu, Wei and Wang, Jian and Yang, Wu and Sun, Zhen and Sun, Xiaoxiao and Wang, Yafang and Lian, Shuo and Zheng, Jiaojiao and Zhou, Yangyang and Shen, Weiming and Hu, Pei and Guo, Jianglong and Wu, Qiangxin and Wang, Siying and Jia, Qi and Yuan, Shengxian and Bernards, René and Qin, Wenxin and Jin, Haojie},
title = {The PKMYT1–ALDOA axis drives chemoresistance in cholangiocarcinoma by enhancing glycolysis and MRE11 lactylation},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2623500123}
}
EUVIMED